Aripiprazole

May 20, 2020

Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia

May 11, 2020

Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis

Nov 13, 2019

Otsuka Announces Retirement of President & Chief Executive Officer William H. Carson, M.D.

Oct 17, 2018

Neurana Pharmaceuticals to Present Tolperisone Phase 1 Clinical Data at the 2018 ACR/ARHP Annual Meeting

Jul 02, 2018

FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia

May 29, 2018

Is This Antipsychotic a Crapshoot?

Apr 30, 2018

Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting

Jan 18, 2018

New Real World Evidence Shows that Long-acting Antipsychotics Reduce Risk of Mortality for Patients Living with Schizophrenia Compared to Oral Antipsychotics

Jan 11, 2018

Psychiatry's Brave New World--FDA Approves Digital Sensor in Antipsychotic Drug to Enforce Prescription Compliance

Nov 14, 2017

Otsuka And Proteus® Announce The First U.S. FDA Approval Of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)

Nov 13, 2017

FDA approves pill with sensor that digitally tracks if patients have ingested their medication

Nov 08, 2017

Schizophrenia Drugs Market Worth $7.9 Billion by 2022 | CAGR: 2.5%: Grand View Research, Inc.